Product Description
Mechanisms of Action: CXCR2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystic Fibrosis|Colitis, Ulcerative
Phase 1: Chronic Obstructive Pulmonary Disease|Cystic Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00605761 |
CF2110398 | P1 |
Completed |
Cystic Fibrosis |
2008-12-01 |
2019-03-18 |
Treatments |
|
NCT00615576 |
CR2111256 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2008-07-24 |
2019-03-18 |
Treatments |
|
NCT00551811 |
CR2100597 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2008-07-22 |
2019-03-22 |
Treatments |
|
NCT00504439 |
CR2100609 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2007-09-06 |
2019-03-21 |
Treatments |
|
NCT00903201 |
NCT00903201 | P2 |
Completed |
Cystic Fibrosis |
2010-12-29 |
2019-03-18 |
Treatments |
|
2010-018738-27 |
2010-018738-27 | P2 |
Completed |
Cystic Fibrosis |
2010-12-29 |
2022-03-13 |
Treatments |
|
NCT00748410 |
CUC111342 | P2 |
Terminated |
Colitis, Ulcerative |
2009-12-12 |
2019-03-18 |
Treatments |
|
2007-005520-32 |
2007-005520-32 | P2 |
Terminated |
Colitis, Ulcerative |
2009-10-01 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|